RU94040361A - AEROSOL PHARMACEUTICAL COMPOSITION, SPRAYER FOR DELIVERY OF THE COMPOSITION, DOSAGE INHALATOR, METHOD FOR TREATING RESPIRATORY DISEASES, METHOD FOR PRODUCING THE COMPOSITION - Google Patents

AEROSOL PHARMACEUTICAL COMPOSITION, SPRAYER FOR DELIVERY OF THE COMPOSITION, DOSAGE INHALATOR, METHOD FOR TREATING RESPIRATORY DISEASES, METHOD FOR PRODUCING THE COMPOSITION

Info

Publication number
RU94040361A
RU94040361A RU94040361/14A RU94040361A RU94040361A RU 94040361 A RU94040361 A RU 94040361A RU 94040361/14 A RU94040361/14 A RU 94040361/14A RU 94040361 A RU94040361 A RU 94040361A RU 94040361 A RU94040361 A RU 94040361A
Authority
RU
Russia
Prior art keywords
composition according
composition
propellant
paragraphs
beclomethasone dipropionate
Prior art date
Application number
RU94040361/14A
Other languages
Russian (ru)
Other versions
RU2120285C1 (en
Inventor
Джон Нил Филип
Джеймс Тэйлор Энтони
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929202519A external-priority patent/GB9202519D0/en
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of RU94040361A publication Critical patent/RU94040361A/en
Application granted granted Critical
Publication of RU2120285C1 publication Critical patent/RU2120285C1/en

Links

Claims (20)

1. Фармацевтическая аэрозольная композиция, отличающаяся тем, что включает: (а) моногидрат беклометазондипропионата с размером частиц в основном менее 20 мкм; (в) по крайней мере 0,015% воды от массы композиции в дополнение к кристаллизационной воде, связанной в моногидрате и (с) фторуглеродный или содержащий водород хлорфтоуглеродный пропеллент.1. A pharmaceutical aerosol composition, characterized in that it includes: (a) beclomethasone dipropionate monohydrate with a particle size of substantially less than 20 microns; (c) at least 0.015% of the water by weight of the composition in addition to crystallization water bound in the monohydrate; and (c) a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant. 2. Фармацевтическая аэрозольная композиция, отличающаяся тем, что состоит в основном из моногидрата беклометазондипропионата, по крайней мере 0,015 мас. % и одного или более фторуглеродных или содержащих водород хлорфторуглеродных носителей. 2. Pharmaceutical aerosol composition, characterized in that it consists mainly of beclomethasone dipropionate monohydrate, at least 0.015 wt. % and one or more fluorocarbon or hydrogen-containing chlorofluorocarbon carriers. 3. Композиция по п. 1 или 2, отличающаяся тем, что включает от 0,015 по 0,1 мас.% добавленной воды. 3. The composition according to p. 1 or 2, characterized in that it comprises from 0.015 to 0.1 wt.% Added water. 4. Композиция по любому из пп. 1 - 3, отличающаяся тем, что включает по крайней мере 0,026 мас.% добавленной воды. 4. The composition according to any one of paragraphs. 1 to 3, characterized in that it includes at least 0.026 wt.% Added water. 5. Композиция по любому из пп. 1 - 4, отличающаяся тем, что включает от 0,026 до 0,08 мас.% добавленной воды. 5. The composition according to any one of paragraphs. 1 to 4, characterized in that it includes from 0.026 to 0.08 wt.% Added water. 6. Композиция по любому из пп. 1 - 5, отличающаяся тем, что носитель включает С1-4-фторуглерод, содержащий водород.6. The composition according to any one of paragraphs. 1 to 5, characterized in that the carrier comprises a C 1-4 fluorocarbon containing hydrogen. 7. Композиция по п. 6, отличающаяся тем, что носитель включает 1,1,1,2,3,3,3-гептафтор-н-пропан. 7. The composition according to p. 6, characterized in that the carrier comprises 1,1,1,2,3,3,3-heptafluoro-n-propane. 8. Композиция по п. 6, отличающаяся тем, что пропеллент включает 1,1,1,2-тетрафторэтан. 8. The composition according to p. 6, characterized in that the propellant includes 1,1,1,2-tetrafluoroethane. 9. Композиция по п. 1 или 2, отличающаяся тем, что включает от 0,03 до 0,08 мас.% добавленной воды и 1,1,1,2-тетрафторэтан в качестве пропеллента. 9. The composition according to p. 1 or 2, characterized in that it comprises from 0.03 to 0.08 wt.% Added water and 1,1,1,2-tetrafluoroethane as a propellant. 10. Композиция по п. 1 или 2, отличающаяся тем, что включает от 0,02 до 0,05 мас. % добавленной воды и 1,1,1,2,3,3,3-гептафтор-н-пропан в качестве пропеллента. 10. The composition according to p. 1 or 2, characterized in that it includes from 0.02 to 0.05 wt. % added water and 1,1,1,2,3,3,3-heptafluoro-n-propane as a propellant. 11. Композиция по любому из пп. 1 - 10, отличающаяся тем, что моногидрат беклометазондипропионата присутствует в количестве от 0,005 до 10% (мас. /мас.) от общей массы композиции. 11. The composition according to any one of paragraphs. 1 to 10, characterized in that beclomethasone dipropionate monohydrate is present in an amount of from 0.005 to 10% (w / w) of the total weight of the composition. 12. Композиция по любому из пп. 1 - 11, отличающаяся тем, что содержит один или более дополнительных активных ингредиентов. 12. The composition according to any one of paragraphs. 1 to 11, characterized in that it contains one or more additional active ingredients. 13. Композиция по п. 12, отличающаяся тем, что включает салметерол или салбутамол или их фармацевтически пригодную соль в комбинации с моногидратом беклометазондипропионата. 13. The composition according to p. 12, characterized in that it comprises salmeterol or salbutamol or a pharmaceutically acceptable salt thereof in combination with beclomethasone dipropionate monohydrate. 14. Композиция по п. 13, отличающаяся тем, что включает салбутамол и моногидрат беклометазондипропионата. 14. The composition according to p. 13, characterized in that it includes salbutamol and beclomethasone dipropionate monohydrate. 15. Композиция по п. 13, отличающаяся тем, что включает ксинофоат сальметерола и моногидрат беклометазондипропионата. 15. The composition according to p. 13, characterized in that it comprises salmeterol xinophoate and beclomethasone dipropionate monohydrate. 16. Композиция по любому из пп. 1 - 15, отличающаяся тем, что вдыхаемая фракция составляет 20% или более лекарственного средства. 16. The composition according to any one of paragraphs. 1 to 15, characterized in that the respirable fraction is 20% or more of the drug. 17. Баллончик, подходящий для доставки фармацевтической аэрозольной композиции, отличающийся тем, что включает контейнер, способный выдерживать давление используемого пропеллента, указанный контейнер закрыт дозировочным клапаном и содержит фармацевтическую аэрозольную композицию, состоящую из: (а) моногидрата беклометазондипропионата, размер частиц которого в основном менее 20 мкм; (b) по крайней мере 0,015 мас.% воды от массы композиции в дополнение к кристаллизационной воде, связанной в указанном моногидрате и (с) фторуглеродный или содержащий водород хлорфторуглеродный пропеллент. 17. A canister suitable for delivering a pharmaceutical aerosol composition, characterized in that it includes a container capable of withstanding the pressure of the propellant used, said container is closed by a metering valve and contains a pharmaceutical aerosol composition consisting of: (a) beclomethasone dipropionate monohydrate, the particle size of which is generally less than 20 microns; (b) at least 0.015 wt.% water by weight of the composition in addition to crystallization water bound in said monohydrate; and (c) a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant. 18. Дозировочный ингалятор, отличающийся тем, что включает баллончик по п. 17, снабженный подходящим устройством с системой каналов. 18. A metered-dose inhaler, characterized in that it includes a can according to claim 17, equipped with a suitable device with a channel system. 19. Способ лечения респираторных заболеваний, отличающийся тем, что включает введение путем ингаляции эффективного количества фармацевтической аэрозольной композиции, состоящей из: (а) моногидрата беклометазондипропионата, размер частиц которого в основном менее 20 мкм; (b) по крайней мере 0,015% воды от массы композиции в дополнение к кристаллизационной воде, связанной в указанном моногидрате, и (с) фторуглеродный или содержащий водород хлорфторуглеродный пропеллент. 19. A method of treating respiratory diseases, characterized in that it comprises administering by inhalation an effective amount of a pharmaceutical aerosol composition consisting of: (a) beclomethasone dipropionate monohydrate, the particle size of which is generally less than 20 microns; (b) at least 0.015% of the water by weight of the composition in addition to the crystallization water bound in said monohydrate; and (c) a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant. 20. Способ получения фармацевтической аэрозольной композиции по любому из пп. 1 - 16, отличающийся тем, что включает диспергирование лекарственного средства и добавленной воды в пропелленте. 20. A method of obtaining a pharmaceutical aerosol composition according to any one of paragraphs. 1 to 16, characterized in that it includes the dispersion of the drug and the added water in the propellant.
RU94040361A 1992-02-06 1993-02-02 Aerosol pharmaceutic composition, bottle for storage and delivery of aerosol pharmaceutic composition, method of treatment of respiratory diseases, composition preparation method RU2120285C1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9202519.6 1992-02-06
GB929202519A GB9202519D0 (en) 1992-02-06 1992-02-06 Medicaments

Publications (2)

Publication Number Publication Date
RU94040361A true RU94040361A (en) 1998-02-10
RU2120285C1 RU2120285C1 (en) 1998-10-20

Family

ID=10709929

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94040361A RU2120285C1 (en) 1992-02-06 1993-02-02 Aerosol pharmaceutic composition, bottle for storage and delivery of aerosol pharmaceutic composition, method of treatment of respiratory diseases, composition preparation method

Country Status (31)

Country Link
US (2) US5695744A (en)
EP (1) EP0625046B1 (en)
JP (1) JP3675474B2 (en)
CN (1) CN1048394C (en)
AP (1) AP419A (en)
AT (1) ATE157875T1 (en)
AU (1) AU667074B2 (en)
BG (1) BG61862B1 (en)
CA (1) CA2128688A1 (en)
CZ (1) CZ281942B6 (en)
DE (1) DE69313825T2 (en)
DK (1) DK0625046T3 (en)
ES (1) ES2106360T3 (en)
GB (1) GB9202519D0 (en)
GE (1) GEP19991820B (en)
GR (1) GR3025363T3 (en)
HK (1) HK1009588A1 (en)
HU (2) HUT68986A (en)
IL (1) IL104628A (en)
IS (1) IS1622B (en)
MX (1) MX9300620A (en)
MY (1) MY108748A (en)
NO (1) NO306453B1 (en)
NZ (1) NZ246889A (en)
OA (1) OA10091A (en)
RO (1) RO118173B1 (en)
RU (1) RU2120285C1 (en)
SK (1) SK279291B6 (en)
TW (1) TW299234B (en)
WO (1) WO1993015741A1 (en)
ZA (1) ZA93800B (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919435A (en) * 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
AU663905B2 (en) 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
ATE150296T1 (en) 1991-12-18 1997-04-15 Minnesota Mining & Mfg AEROSOL COMPOSITIONS FOR MEDICINAL SUSPENSIONS
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US5833950A (en) * 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
CZ288146B6 (en) * 1994-12-22 2001-05-16 Astra Ab Pharmaceutical aerosol preparation, process of its preparation and use
US6013245A (en) * 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
EE03509B2 (en) 1995-06-27 2015-02-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ethanol containing medicinal compositions for generating propellantfree aerosols
HU224224B1 (en) * 1997-01-14 2005-06-28 Lts Lohmann Therapie-Systeme Gmbh Expandable gastro-retentive therapeutic system with controlled active substance release in the gastro-intestinal tract
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
CN1269722A (en) * 1997-03-18 2000-10-11 Basf公司 Method and composition for modulating responsiveness to corticosteroids
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
TWI243687B (en) * 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
IT1303692B1 (en) * 1998-11-03 2001-02-23 Chiesi Farma Spa PROCEDURE FOR THE PREPARATION OF SUSPENSIONS OF PARTICLES OF DRUGS TO BE ADMINISTERED BY INHALATION.
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US6540982B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6540983B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6548049B1 (en) 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6565833B1 (en) 2000-05-01 2003-05-20 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6447750B1 (en) 2000-05-01 2002-09-10 Aeropharm Technology Incorporated Medicinal aerosol formulation
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
DK1280520T4 (en) 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU2001247123A1 (en) * 2000-07-19 2002-02-05 Aeropharm Technology, Inc. A medicinal aerosol formulation
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
EP1458360B1 (en) 2001-12-19 2011-05-11 Novartis AG Pulmonary delivery of aminoglycosides
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
AU2007231727B2 (en) * 2002-09-03 2010-12-16 Kos Life Sciences, Inc. Water stabilized medicinal aerosol formulation
ATE390125T1 (en) * 2003-03-20 2008-04-15 Boehringer Ingelheim Pharma FORMULATION FOR A MESSAGE INHALER USING HYDRO-FLUORO-ALKANES AS PROpellants
US20040191176A1 (en) * 2003-03-28 2004-09-30 Kaplan Leonard W Formulations for treatment of pulmonary disorders
JP5053635B2 (en) * 2003-08-29 2012-10-17 グラクソ グループ リミテッド Medical metered dose inhaler and method related thereto
AR041873A1 (en) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab A PHARMACEUTICAL FORMULATION IN ADEQUATE AEROSOL FOR ORAL OR NASAL INHALATION CONTAINING GLUCOCORTICOIDS IN A STABLE SOLUTION TO STORAGE; A METHOD FOR STABILIZING FORMULATIONS AND USE OF A STABILIZING AGENT
US20050238632A1 (en) * 2004-04-23 2005-10-27 Alburty David S Propellant formulations
ES2391563T5 (en) * 2004-07-02 2022-10-26 Boehringer Ingelheim Int Aerosol suspension formulations with TG 227 ea as propellant
BRPI0606736A2 (en) 2005-02-11 2009-07-21 Argenta Discovery Ltd combination of methylxanthine compounds and steroids to treat chronic respiratory diseases
US9084799B2 (en) 2005-02-11 2015-07-21 Pulmagen Therapeutics (Synergy) Limited Inhaled combination therapy
DE102006017320A1 (en) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
EP2425820B1 (en) 2007-02-11 2015-04-08 MAP Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
RU2504402C1 (en) * 2012-11-20 2014-01-20 Шолекс Девелопмент Гмбх Inhalation formulation in form of aerosol for treating bronchial asthma and chronic obstructive pulmonary disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI63672C (en) * 1980-05-19 1983-08-10 Orion Yhtymae Oy FOERFARANDE FOER FRAMSTAELLNING AV EN BLANDNING AV BEKLOMETASONDIPROPIONAT OCH TRIKLORFLUORMETAN ELLER DIKLORDIFLUORMETAN
KR890000664B1 (en) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 Preparation method for micronised be clomethasone dispropionate mono-hydrate
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
DE69105212T2 (en) * 1990-10-18 1995-03-23 Minnesota Mining & Mfg AEROSOL PREPARATION CONTAINING BECLOMETASON 17.21 DIPROPIONATE.

Similar Documents

Publication Publication Date Title
RU94040361A (en) AEROSOL PHARMACEUTICAL COMPOSITION, SPRAYER FOR DELIVERY OF THE COMPOSITION, DOSAGE INHALATOR, METHOD FOR TREATING RESPIRATORY DISEASES, METHOD FOR PRODUCING THE COMPOSITION
EP1143931B1 (en) Pulmonary drug delivery
CA2353959C (en) A medicinal aerosol formulation
JP5599961B2 (en) Pharmaceutical composition
EP0588897B1 (en) Non-chlorofluorocarbon aerosol formulations
DE69233076T2 (en) aerosol preparations
EP0587790B1 (en) Non-chlorofluorocarbon aerosol formulations
CN1098680C (en) Medicine
EP0918507B2 (en) Aerosol formulations
RU98118908A (en) PHARMACEUTICAL DELIVERY CYLINDER, DOSING INHALER
US20030206870A1 (en) Pharaceutical aerosol composition
MY108748A (en) Medicaments
SK284430B6 (en) Pharmaceutical composition for use in an aerosol inhaler, aerosol inhaler and method of filling an aerosol inhaler
GB9425160D0 (en) Medicaments
US5891420A (en) Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
WO2000047203A1 (en) Formulation and system for intra-oral delivery of pharmaceutical agents
GR3018168T3 (en) Medicaments.
RU2006112589A (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING PREMATURE EJACULATION USING PULMONARY INHALATION
US5536444A (en) Compressed-gas packages using polyoxyethylene glyceryl fatty-acid esters as suspension stabilizers and valve lubricants
CA2125666A1 (en) Medicaments
EA021604B1 (en) Aerosol formulation for treating asthma and copd
EP0630229A1 (en) Pressurized gas packagings using polyoxyethylene glyceryl-obates.
O Callaghan et al. The history of inhaled drug therapy
US3608065A (en) Aerosol composition containing a vasoconstrictor
AU774250B2 (en) Pharmaceutical aerosol composition